首页 | 本学科首页   官方微博 | 高级检索  
检索        


Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair®)
Authors:J D M Hughes  T Olynyc  H Chapdelaine  L Segal  B Miedzybrodzki  M Ben‐Shoshan
Institution:1. University of Ottawa – Department of Medicine, Ottawa, Ontario, Canada;2. Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada;3. Department of Medicine, Centre Hospitalier Universitaire de Montreal, Montreal, Quebec, Canada;4. Department of Medicine, Community Pediatrics, University of Ottawa, Ottawa, Ontario, Canada;5. Department of Pediatrics, Division of Allergy and Clinical Immunology and Dermatology, Department of Pediatrics, Montreal Children's Hospital, Montreal, Quebec, Canada;6. Department of Medicine, Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
Abstract:Omalizumab (Xolair®) is an anti‐IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab in paediatric patients with cutaneous mastocytosis.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号